Zura Bio Ltd (ZURA)
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Zura Bio Limited
NASDAQ:ZURAHealthcare · Biotechnology
AHAfter hours-0.48%$1.03
Prev close$1.08-4.17%Close$1.03-0.48%Now$1.03
Close$1.03-4.17%
Mkt Cap$99.7M
EV-$9.71M
Float68.65M
O/S96.33M
VOL3.52M sh
$ Vol$3.58M
RVOL0.47×
Inst Own71.9%
Net Cash/Sh+$1.14
EarningsMar 31 · in 4mo
Dilution
MCap$99.7MFloat68.65MO/S96.33M
Dilution
Financials Summary
Revenue$0
Net Income-$68.65M
Total Assets$113.95M
Free Cash Flow-$64.93M
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$101.54M
Shares Outstanding
Short Interest
No short interest data available.
Split History
No splits on record
Nothing in ZURA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$113.95M
Liabilities$12.41M
Accounts Receivable$0
Accounts Payable$1.28M
Inventory$0
PP&E (Net)$126K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - |
| Research and Development | $42.08M | $24.4M | $44M | $23.69M | $0 |
| Selling, General, and Administrative | $33.16M | $30.79M | $18.64M | $3.47M | $1.09M |
| Other | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $75.25M | $55.19M | $62.64M | $27.16M | $1.09M |
| Operating Income (EBIT) | -$75.25M | -$55.19M | -$62.64M | -$27.16M | -$1.09M |
| Operating Margin | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $6.34M | $8M | $2.19M | $570 | $23K |
| Other Income (Expense) | $6.6M | $2.79M | $2.08M | -$171K | $9.51M |
| Income Before Tax (EBT) | -$68.65M | -$52.4M | -$60.56M | -$27.33M | $8.42M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$68.65M | -$52.4M | -$60.36M | -$25.74M | $8.42M |
| Net Income Margin | - | - | - | - | - |
| Supplementary Data | |||||
| EPS | -1.06 | -0.60 | -2.09 | -1.88 | 0.40 |
| Diluted EPS | -1.06 | -0.60 | -2.09 | -1.88 | 0.40 |
| Weighted Average OS | 94.16M | 75.07M | 33.06M | 17.25M | 17.25M |
| EBITDA | -$68.6M | -$52.39M | -$60.56M | -$27.33M | $8.42M |
| EBITDA Margin | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $109.41M | $176.5M | $99.81M | $1.57M |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $109.41M | $176.5M | $99.81M | $1.57M |
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $2.9M | $2.25M | $1.04M | $189K |
| Total Current Assets | $112.31M | $178.74M | $100.84M | $1.78M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $126K | $91K | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.51M | $698K | $0 | $3.49M |
| Total Long-Term Assets | $1.64M | $789K | $0 | $3.49M |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $113.95M | $179.53M | $100.84M | $5.26M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $1.28M | $733K | $2.75M | $2.01M |
| Short-Term Debt | $0 | $0 | $0 | $7.76M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $3.32M | $1.71M | $1.2M | $2.77M |
| Total Current Liabilities | $12.41M | $19.51M | $20.3M | $14.82M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $990K | $12.5M |
| Total Long-Term Liabilities | $0 | $0 | $990K | $12.5M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $12.41M | $19.51M | $21.29M | $27.32M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $0 | $0 |
| Common Stock | $7K | $7K | $4K | $0 |
| Retained Earnings | -$224.55M | -$155.9M | -$103.49M | -$32.06M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $326.08M | $302.7M | $162.82M | $0 |
| Total Equity | $101.54M | $146.81M | $59.33M | -$32.06M |
| Minority Interest | $0 | $13.2M | $20.22M | $10M |
| Total Liabilities and Equity | $113.95M | $166.33M | $80.62M | -$4.74M |
| Supplementary Data | ||||
| Total Debt | $0 | $0 | $0 | $7.76M |
| Net Debt | -$109.41M | -$176.5M | -$99.81M | $6.19M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Operating Activities | |||||
| Net Income | -$68.65M | -$52.4M | -$60.56M | -$27.33M | $8.42M |
| Depreciation & Amortization | $49K | $9K | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $12.33M | $16.8M | $9.65M | $334K | $0 |
| Changes in Working Capital: | |||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $3K |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$2.16M | $4.21M | $0 | $288K | $0 |
| Other Working Capital | -$1.47M | -$1.91M | $5.12M | $3.25M | -$238K |
| Total Working Capital Change | -$3.63M | $2.31M | $5.12M | $3.54M | -$236K |
| Other Non-Cash Items | -$4.91M | $5.21M | $30.74M | $22.26M | -$9.28M |
| Net Cash from Operating | -$64.81M | -$28.08M | -$15.05M | -$1.2M | -$1.1M |
| Investing Activities | |||||
| Capital Expenditures | -$113K | -$75K | -$8M | -$12M | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | -$139.38M |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | -$5M | $0 | $0 | $0 |
| Net Cash from Investing | -$113K | -$5.08M | -$8M | -$12M | -$139.38M |
| Financing Activities | |||||
| Debt Repaid | - | - | $10M | - | - |
| Common Stock Issuance | $5.2M | $60.76M | $116.41M | $0 | $140.82M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$7.37M | $49.09M | $14.89M | -$2.83M | $505K |
| Net Cash from Financing | -$2.16M | $109.84M | $121.29M | $14.77M | $141.21M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$67.09M | $76.69M | $98.24M | $1.57M | $729K |
| Supplementary Data | |||||
| Operating Cash Flow | -$64.81M | -$28.08M | -$15.05M | -$1.2M | -$1.1M |
| Capital Expenditure | -$113K | -$75K | -$8 | -$12 | -$4 |
| Free Cash Flow | -$64.93M | -$28.15M | -$23.05M | -$13.2M | -$1.1M |
| Cash at Beginning | $176.5M | $99.81M | $1.57M | $0 | $0 |
| Cash at End | $109.41M | $176.5M | $99.81M | $1.57M | $729K |